Skip to main content
Premium Trial:

Request an Annual Quote

Don Van Dyke, Stan Yakatan, Axel Ullrich

Premium

Don Van Dyke has been hired as vice president of business development at Incogen. Van Dyke most recently served as a consultant to Incogen. Prior to that, he was vice president of sales and marketing at Molecular Mining and president and CEO of Bio Image.


Phenomenome Discoveries of Saskatoon, Saskatchewan, Canada, has appointed Stan Yakatan to its board of directors. Yakatan is president of Katan Associates, and has 30 years’ experience as an entrepreneur. He has founded or co-founded more than 15 companies, and served as an executive at New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific, and Biosearch. Phenomenome Discoveries uses a proprietary metabolite analysis and bioinformatics platform to study biological samples.


The Singapore Onco Genome Laboratory has tapped Axel Ullrich from the Max Planck Institute of Biochemistry in Martinsried, Germany, to lead its research team. The laboratory is a joint research program between the Max Planck Society and Singapore’s Agency for Science, Technology and Research. Ullrich will lead an effort at the center to guild a gene database of cancer cell lines and tumor tissues using a new gene identification signature technology developed by the Genome Institute of Singapore.

Filed under

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.